evipedia.ai
← Back

Cyanidin-3-Glucoside for Health & Longevity

Evidence Review created on 09/08/2026 using AI4L / Opus 5

Also known as: C3G, Cyanidin-3-O-Glucoside, Cyanidin 3-Glucoside, Kuromanin, Chrysanthemin

Motivation

Cyanidin-3-glucoside is the red-purple pigment that colors blackberries, elderberries, black rice, blackcurrants and purple corn. It belongs to the anthocyanins, a group of plant pigments found in deeply colored fruits and vegetables, and it is the most abundant anthocyanin in the human diet. Interest in it comes from a simple observation: populations that eat more brightly colored fruit tend to have healthier hearts and metabolisms, and laboratory work points to this molecule as one of the pigments doing the work.

Berries have been food and folk medicine for centuries, and isolated anthocyanin capsules have been sold since the 1990s. Human trials have since tested purified berry-pigment preparations for blood fats, blood sugar and blood vessel function, with results ranging from clearly positive to flatly negative. Only a small fraction of a swallowed dose reaches the bloodstream intact, and most of what circulates are breakdown products.

This review examines what is known about cyanidin-3-glucoside as a health and longevity intervention: how the body absorbs and transforms it, which effects human trials support and which they do not, how strong the underlying evidence is, what risks and interactions have been described, and how it is dosed, sourced and monitored in practice.

Benefits - Risks - Protocol - Conclusion

A short set of high-level resources that introduce cyanidin-3-glucoside and the anthocyanin class from chemical, clinical and longevity perspectives.

Note: two priority platforms are unrepresented because nothing on them treats the subject in depth. On peterattiamd.com, anthocyanins surface only as a one-clause example inside a critique of flavonoid-diversity epidemiology; on chriskresser.com they appear only as passing mentions inside broader phytochemical and wine articles.

Grokipedia

Cyanidin

Grokipedia carries no dedicated cyanidin-3-glucoside article; this entry on cyanidin, the sugar-free parent molecule, is its primary page for the compound, covering chemistry, dietary sources, absorption and reported biological activity.

Examine

Cyanidin

Examine’s dedicated page for the compound: it frames cyanidin-3-glucoside as the most readily absorbed anthocyanin, summarizes the glucose-lowering data, flags how little is absorbed, and notes the very high doses used in animal work.

ConsumerLab

ConsumerLab has no article, product review or clinical update covering cyanidin-3-glucoside. Its anthocyanin-related content is limited to reviews of whole-berry supplements such as elderberry, bilberry and acai, none of which tests isolated cyanidin-3-glucoside products.

Systematic Reviews

Pooled analyses that bear directly on cyanidin-3-glucoside, selected for structure-specific relevance, size, recency and citation weight.

Trade-off coverage: the claimed benefits are represented above, and the structure-stratified and cognition analyses cover the principal forgone benefit. PubMed holds no systematic review or meta-analysis of harms from cyanidin-3-glucoside or purified anthocyanins, so the risk side of the trade-off is unrepresented in this section.

Mechanism of Action

Cyanidin-3-glucoside is cyanidin joined to a glucose unit at ring position 3. In stomach acid it is a stable red flavylium cation (a positively charged, acid-stable pigment form); at intestinal and blood acidity it converts to colorless forms and breaks apart.

Absorption is partly carrier-mediated, through the sugar transporters SGLT1 and GLUT2 (proteins that carry glucose across the gut lining), and partly through direct gastric uptake. Relative availability to the body, measured with a labeled dose, is roughly 12%, and the intact molecule peaks in blood at nanomolar concentrations within one to two hours. Most circulating material is metabolite: protocatechuic acid, phloroglucinaldehyde and downstream phenolic, hippuric and ferulic acids, produced by spontaneous breakdown, gut bacteria, and liver phase II enzymes (which attach sulfate or glucuronic acid to speed excretion). Labeled metabolites persist 12 to 48 hours, giving apparent half-lives of about 12 to 50 hours. Animal distribution work finds low but measurable amounts in liver, kidney and brain.

Proposed actions include activating AMPK (a cellular fuel gauge that raises glucose uptake), activating Nrf2 (a switch that turns on the cell’s own antioxidant genes), suppressing NF-κB (the master switch for inflammatory genes), and inhibiting cholesteryl ester transfer protein, which moves cholesterol from HDL (the particle returning cholesterol to the liver) toward LDL (the particle linked to artery disease).

Two explanations compete. One holds the intact glucoside is the active agent; the other, which fits its poor absorption better, holds that the small phenolic breakdown products carry most of the activity.

Historical Context & Evolution

Anthocyanins were named and crudely isolated in 1835 by Ludwig Marquart, and their structures were solved by Richard Willstätter in the 1910s, work that contributed to his Nobel Prize. For most of that period the pigments interested chemists as dyes and, later, as a permitted food color.

The medicinal thread began in post-war Europe, where standardized bilberry extracts containing cyanidin-3-glucoside were sold from the 1960s for capillary fragility and diabetic eye disease, supported by small European trials and by wartime anecdotes about improved night vision in aircrew. Those anecdotes have never been reproduced under controlled testing; the capillary-permeability findings were real but small and rarely replicated outside the clinics that generated them.

Health-optimization interest arrived with the 1990s antioxidant era, when berry extracts scored highest on the oxygen radical absorbance capacity assay. Isolated anthocyanin capsules reached the Norwegian market in the early 2000s, and the first substantial human trial appeared in 2009. That commercial preparation went on to supply the study material for most influential purified-anthocyanin trials, a manufacturer interest that runs through much of the literature cited below.

The framing has since shifted twice. The US Department of Agriculture withdrew its antioxidant capacity database in 2012 as physiologically unsound, and a 2013 isotope-tracer study showed only about a tenth of a dose reaches the body, mostly as breakdown products. Current work therefore emphasizes cell signaling and gut metabolites rather than direct free-radical scavenging — a reframing of the earlier findings, not a refutation of them.

Expected Benefits

High 🟩 🟩 🟩

Improved Endothelial Function

Cyanidin-3-glucoside improves flow-mediated dilation, the ultrasound-measured artery widening that predicts cardiovascular outcomes. The proposed mechanism is greater nitric oxide availability in the vessel wall through inhibition of NADPH oxidase (an enzyme that generates free radicals inside blood vessels). The evidence basis is a 2026 systematic review and meta-analysis of 65 randomized trials, which graded the acute effect strong and the sustained effect moderate, and found the cyanidin subgroup effective on sustained dosing. Contributing trials mostly ran four to twelve weeks in healthy adults.

Magnitude: Sustained supplementation raised flow-mediated dilation by 1.62 percentage points (95% CI, the confidence interval or range in which the true effect most likely lies, 1.21–2.04) in the cyanidin subgroup; single doses raised it 1.50 points across all anthocyanin types.

Improved Glycemic Control in Impaired Glucose Regulation

In people with prediabetes or type 2 diabetes, purified anthocyanin capsules improve blood sugar handling. The proposed mechanism is reduced formation of advanced glycation end products (sugar-damaged proteins that blunt insulin signaling) together with AMPK-driven glucose uptake in muscle. The evidence basis is two randomized double-blind trials: 320 mg daily for 24 weeks in type 2 diabetes and 160 mg daily for 12 weeks in impaired glucose tolerance. Both used mixed berry anthocyanins containing cyanidin-3-glucoside as a major but not sole component; the isolated molecule is untested here.

Magnitude: Fasting glucose fell 8.5% and the insulin resistance index 13% over 24 weeks in type 2 diabetes; in impaired glucose tolerance, more than half the supplemented group returned to normal glucose tolerance against under a third on placebo.

Medium 🟩 🟩

Lower Cardiovascular Event and Mortality Risk at Higher Dietary Intake

People whose habitual diets are richest in anthocyanins have fewer coronary events and lower cardiovascular death rates, a signal consistent across pooled prospective cohorts and a large US survey cohort. It is biologically coherent with the artery-dilation and inflammation findings. It is nonetheless observational and measures total dietary anthocyanins rather than cyanidin-3-glucoside capsules, so confounding by overall diet quality cannot be excluded. Stroke risk is not reduced in the same analyses.

Magnitude: Highest against lowest intake gave a relative risk (the ratio of event rates between groups) of 0.91 (95% CI 0.83–0.99) for coronary heart disease and 0.92 (0.87–0.97) for cardiovascular death; all-cause mortality hazard ratio (the relative event rate over time) was 0.68 (0.52–0.89) among 11,959 adults.

Low 🟩

Reduced Systemic Inflammatory Markers ⚠️ Conflicted

Purified anthocyanins lower markers of low-grade inflammation, plausibly by suppressing NF-κB signaling. A dose-ranging trial in 169 adults with dyslipidemia (abnormal blood fats) cut interleukin-6 and tumor necrosis factor alpha (inflammatory messengers), and a 44-trial pooling agreed; an obesity pooling moved only an adhesion marker. Net reading: modest and inconsistent.

Magnitude: At 320 mg daily for 12 weeks, interleukin-6 fell 40% and tumor necrosis factor alpha 21% against baseline; pooled across 44 trials C-reactive protein fell 0.028 mg/dL, and vascular cell adhesion molecule-1 fell 53.6 ng/mL in the obesity pooling.

Blood Lipid Improvement ⚠️ Conflicted

Early trials in dyslipidemia and diabetes reported large LDL and HDL shifts, attributed to cholesteryl ester transfer protein inhibition. Structure-stratified pooling and an isolated-compound crossover trial contradict this for cyanidin. Net reading: the lipid effect is not established for cyanidin-3-glucoside.

Magnitude: The 12-week dyslipidemia trial gave LDL −13.6% and HDL +13.7% against placebo; against this, 28 days of 320 mg isolated black-rice cyanidin-3-glucoside changed no lipid measure, and cyanidin-stratified pooling showed no significant lipid effect.

Cognitive Processing Speed ⚠️ Conflicted

Anthocyanin supplements may preserve processing speed in older adults, possibly via improved cerebral blood flow. One meta-analysis of 13 trials found a speed benefit but none for memory or attention; another found no effect on any memory domain, and the largest dedicated trial missed its primary endpoint. Net reading: unproven.

Magnitude: Processing speed improved with a pooled standardized effect of 0.26 (95% CI 0.08–0.44); no memory domain reached significance, and the 201-participant 24-week trial found no overall benefit.

Body Weight and Adiposity ⚠️ Conflicted

Anthocyanin intake is widely promoted for fat loss. One meta-analysis of 11 trials found a small body mass index reduction confined to non-obese participants and to doses under 300 mg daily; a larger meta-analysis of 31 trials found no effect on any body measurement. Net reading: no dependable weight effect.

Magnitude: Body mass index fell 0.36 kg/m² (95% CI −0.58 to −0.13) in the positive pooling and not at all in the larger one; body weight and waist circumference were unchanged in both.

Liver Fat and Liver Enzymes ⚠️ Conflicted

A pilot trial in nonalcoholic fatty liver disease (fat accumulation in the liver without alcohol) reported improved liver enzymes on 320 mg daily. A meta-analysis of 12 trials in metabolic disorders found no change in either liver enzyme. Net reading: not supported beyond the pilot.

Magnitude: The pilot gave alanine aminotransferase −19.1% against +3.1% on placebo; pooled across 12 trials that enzyme changed −0.92 U/L (95% CI −4.19 to 2.35) and aspartate aminotransferase −1.22 U/L (−3.43 to 0.99), both non-significant.

Exercise Recovery and Performance ⚠️ Conflicted

Anthocyanin-rich blackcurrant extracts, which carry cyanidin and delphinidin glucosides, are taken before endurance work. A meta-analysis of nine trials found a small performance gain, but muscle-damage recovery trials split between benefit and no effect. Net reading: a modest, unreliable ergogenic (performance-enhancing) signal.

Magnitude: Pooled sport-performance effect size 0.45 (95% CI 0.09–0.81) at 105–210 mg of blackcurrant anthocyanins taken before exercise.

Focusing-Muscle Function and Eye Strain

Bilberry extract standardized for anthocyanins has long been sold for eye strain. A 12-week randomized, placebo-controlled trial in adults doing screen work found objectively improved contraction of the eye’s focusing muscle. That extract is delphinidin-dominant, so the finding is indirect for cyanidin-3-glucoside and untested for the isolated compound.

Magnitude: Direction is positive for objectively measured focusing-muscle contraction after 12 weeks of bilberry anthocyanin intake in screen workers; the literature reports no outcome figure transferable to isolated cyanidin-3-glucoside.

Lower Colorectal Cancer Risk at Higher Dietary Intake

A meta-analysis of seven observational studies links higher anthocyanin intake to less colorectal cancer; a systematic review of cell studies shows invasion slowed via Akt/mTOR (a central driver of cell growth), but in breast rather than colorectal cells. Evidence is very low quality, and no trial has tested the compound.

Magnitude: Highest against lowest anthocyanin intake gave a relative risk of 0.78 (95% CI 0.64–0.95) for colorectal cancer across seven studies; the signal came mainly from case-control studies and no dose-response relationship was found.

Speculative 🟨

Cellular Senescence and Lifespan Extension

Cyanidin quiets senescent cells — non-dividing cells that leak inflammatory signals — in culture, extends lifespan in roundworms through mitochondrial recycling, with better survival in aged mice. No human data exist; the basis is preclinical.

Benefit-Modifying Factors

  • Gut microbiome composition: Most circulating activity comes from bacterial breakdown products such as protocatechuic acid. People with low microbial diversity or recent antibiotic exposure generate less of these metabolites and may see smaller effects.

  • COMT and SULT1A1 variants: Catechol-O-methyltransferase (an enzyme that caps catechol groups with a methyl unit) and sulfotransferase 1A1 (which attaches sulfate) govern how fast metabolites are inactivated. Fast variants shorten exposure; no trial has stratified by them.

  • Baseline inflammation: High-sensitivity C-reactive protein (a fine-grained inflammation marker) predicts response. A reanalysis of the largest cognition trial found benefit only in participants clustering with high inflammatory markers at entry.

  • Baseline lipids and glucose: Effects concentrate in people who start outside optimal ranges. Pooled trials in generally healthy participants show no lipid or glucose change, while trials in dyslipidemia and diabetes show the largest shifts.

  • Pre-existing health conditions: Type 2 diabetes, prediabetes and fatty liver disease are the states in which purified anthocyanins have produced measurable metabolic change. Healthy adults show artery-dilation improvement but little metabolic movement.

  • Sex-based differences: In the US cohort data, the mortality association was clearest in men. Intervention trials rarely publish sex-stratified results, so sex-specific dosing or response cannot yet be described.

  • Age-related considerations: Older adults with stiffer vessels and slower processing speed have more headroom to improve, and the cognition trials that reported signals enrolled participants aged 60 to 80. No upper age limit has been studied.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been reported more often than placebo in more than one controlled trial of purified anthocyanins, so no replicated human adverse-event class exists.

Medium 🟥 🟥

No risk reaches Medium either: no single controlled trial and no observational cohort has linked purified anthocyanin or cyanidin-3-glucoside intake to a defined harm, so the human safety evidence is tolerability reporting rather than event data.

Low 🟥

Gastrointestinal Intolerance

Concentrated berry extracts can cause nausea, loose stools and abdominal discomfort, typically dose-related and self-limiting. Controlled trials of purified anthocyanins up to 320 mg daily for 24 weeks recorded no serious adverse events, and a two-week absorption study found good tolerability. Reports come from drug references, not trial data.

Magnitude: Not quantified in available studies. No controlled trial of purified anthocyanins has published an incidence figure for gastrointestinal complaints; the published trials report only the absence of serious adverse events.

Additive Blood-Glucose Lowering

Purified anthocyanins lower fasting glucose and improve insulin sensitivity in people with diabetes, so adding them to insulin or a sulfonylurea (an older oral drug that forces insulin release) could cause hypoglycemia (blood sugar falling below safe levels). No such event was reported in trials; the risk is inferential.

Magnitude: Fasting glucose fell 8.5% and the insulin resistance index 13% over 24 weeks in treated diabetes; no trial has reported a low-blood-sugar rate, so the added risk alongside glucose-lowering drugs is unquantified.

Adulterated or Underdosed Products

Anthocyanin supplements are a documented adulteration target. Authentication methods have been developed specifically because bilberry ingredients are substituted with cheaper berries or dye-boosted material, so a product may deliver far less cyanidin-3-glucoside than labeled. The harm is therapeutic failure and unquantified exposure rather than toxicity.

Magnitude: Not quantified in available studies. Published authentication work reports analytical method performance rather than the share of marketed products that fail, and no regulator has published a market-wide failure rate for anthocyanin supplements.

Speculative 🟨

Hypersensitivity to Berry-Derived Extracts

Berry extracts have been linked to hives and angioedema (rapid swelling of lips, tongue or throat) in sensitized people. The basis is isolated consumer reports and drug-reference warnings, not controlled data.

Increased Bleeding Tendency With Antithrombotic Drugs

Anthocyanins inhibit platelet clumping in laboratory assays, and berry extracts carry bleeding warnings alongside warfarin or aspirin. No human bleeding event has been attributed to purified anthocyanins; the basis is mechanistic.

Blunted Adaptation to Endurance Training

High-dose antioxidants can suppress the exercise-induced free-radical signals that drive mitochondrial adaptation. Whether anthocyanin doses used in practice do this has never been tested; the concern is extrapolated from other antioxidants.

Reduced Plant-Source Iron Absorption

Polyphenols bind plant-source iron in the gut and reduce its uptake. Cyanidin-3-glucoside has not been tested for this at supplemental doses; the concern is a class extrapolation relevant to menstruating women and vegetarians.

Risk-Modifying Factors

  • CYP2C9 and VKORC1 variants: These govern warfarin sensitivity (the first metabolizes the drug, the second is its target). Carriers of slow variants sit closer to the bleeding threshold, so any added antiplatelet effect matters more for them.

  • Baseline ferritin and hemoglobin: Low iron stores make the polyphenol-iron binding effect consequential. Ferritin below 30 ng/mL turns a theoretical interaction into a practical one; high stores make it irrelevant or mildly favorable.

  • Sex-based differences: Menstruating women carry lower iron reserves and are the group in which reduced plant-source iron absorption could matter. No sex difference in tolerability or adverse events has been reported.

  • Pre-existing health conditions: Bleeding disorders, active peptic ulcer, insulin-treated diabetes with hypoglycemia unawareness, and documented berry allergy each amplify one of the described risks. Fatty liver and diabetes do not raise risk.

  • Age-related considerations: Older adults are more likely to take anticoagulants and sulfonylureas simultaneously, compounding the two interaction-driven risks. No age-specific toxicity has been described up to age 80, the oldest studied.

Key Interactions & Contraindications

  • Warfarin and direct oral anticoagulants (apixaban, rivaroxaban, dabigatran): Caution. Theoretical additive bleeding from platelet inhibition. Practice is to recheck the international normalized ratio (a clotting-time ratio) one to two weeks after warfarin starts, and to hold before invasive procedures.

  • Antiplatelet drugs (clopidogrel, ticagrelor, prasugrel): Caution. Additive inhibition of platelet clumping raises bruising and bleeding risk. No dose change is defined; separate timing does not help, so monitoring for unusual bruising is the practical step.

  • Insulin and insulin secretagogues (glipizide, glyburide, repaglinide): Caution. Additive glucose lowering can produce hypoglycemia. Glucose checks are increased for the first four weeks, and the secretagogue dose reduced if readings trend low.

  • Other glucose-lowering agents (metformin, SGLT2 inhibitors such as empagliflozin, which make the kidney excrete sugar): Monitor. Additive glucose lowering without meaningful hypoglycemia risk on their own; the concern arises only in combination with insulin.

  • Over-the-counter aspirin and NSAIDs (ibuprofen, naproxen, which relieve pain and inflammation): Caution. Additive bleeding tendency and stomach irritation. Dosing with food and avoiding daily high-dose combinations without clinician review are the described precautions.

  • Over-the-counter iron salts (ferrous sulfate, ferrous bisglycinate): Monitor. Polyphenols bind iron and reduce absorption. Separating the two by at least two hours preserves iron uptake.

  • Supplements with additive antiplatelet effects (fish oil, ginkgo, garlic extract, nattokinase, high-dose vitamin E): Caution. Stacking several weak platelet inhibitors raises bleeding risk more than any single one; protocols limit intake to one such agent alongside anticoagulation.

  • Supplements with additive glucose-lowering effects (berberine, alpha-lipoic acid, chromium picolinate, cinnamon extract): Caution. Combined use can lower glucose further than intended in people also taking diabetes medication; introductions are staggered by two weeks with monitoring.

  • Supplements with additive vascular effects (dietary nitrate or beetroot, cocoa flavanols, citrulline): Monitor. All widen vessels through nitric oxide, so blood pressure can fall further than expected in people already on antihypertensive drugs.

  • Other interventions (high-dose antioxidant stacks around training, therapeutic plasma donation, elective surgery): Caution. Antioxidant stacking may blunt training signals; drug-reference guidance for berry extracts calls for a two-week withdrawal before elective surgery.

Populations who should avoid Cyanidin-3-Glucoside:

  • People with documented allergy or anaphylaxis to the source berry (bilberry, blackcurrant, elderberry, black rice).
  • Pregnant or breastfeeding women, given the absence of safety data at supplemental doses.
  • People scheduled for surgery within 14 days.
  • People with a bleeding disorder or platelet count below 50 × 10⁹/L.
  • People with insulin-treated diabetes and hypoglycemia unawareness, unless glucose is actively monitored.

Risk Mitigation Strategies

  • Two-week run-in at 80–160 mg daily: Beginning at half the trial dose before moving to 320 mg daily limits the nausea and loose stools that concentrated berry extracts can cause, and identifies individual intolerance early.

  • Dosing with a meal: Taking the capsules with food rather than on an empty stomach reduces gastric irritation and abdominal discomfort, the most commonly described complaint with concentrated berry extracts.

  • Two-hour separation from iron supplements: Spacing doses preserves plant-source iron absorption, which polyphenols reduce by binding iron in the gut. Most relevant when ferritin is below 30 ng/mL.

  • Intensified glucose checks for four weeks: Protocols for people on insulin or a sulfonylurea add daily fasting and pre-dinner readings through the first month, catching additive glucose lowering before a hypoglycemic episode.

  • Early international normalized ratio rechecks: For anyone on warfarin, two checks in the first fortnight detect any shift in clotting time from the theoretical additive antiplatelet effect before bleeding occurs.

  • Fourteen-day washout before elective surgery: A two-week pause, consistent with drug-reference guidance for berry extracts, removes the theoretical perioperative bleeding contribution and the blood-sugar variability during anesthesia.

  • Label declaring milligrams of cyanidin-3-glucoside plus third-party testing: A label that quantifies the specific pigment and carries an independent certificate of analysis addresses the documented adulteration and underdosing of bilberry ingredients.

  • Four-hour gap between a dose and key training sessions: Separating intake from hard sessions limits any antioxidant interference with the exercise-induced signals that drive mitochondrial adaptation, while preserving daily exposure.

Therapeutic Protocol

  • Standard dose: Practitioners working from the trial literature use 160 mg twice daily of purified berry anthocyanins, the schedule used in the diabetes and dyslipidemia trials. Isolated cyanidin-3-glucoside products typically supply 10–100 mg.

  • Competing approach — food first: The Norwich and Belfast research groups argue for dietary intake of 50–200 mg daily from berries and black rice, on the basis that pooled trials show benefit at dietarily achievable doses.

  • Competing approach — purified extract: The Sun Yat-sen University group under Wenhua Ling standardized the 320 mg daily capsule protocol; the Stavanger group used the same preparation for cognition. Neither approach is established as superior.

  • Best time of day: Split morning and evening with meals. For exercise use, blackcurrant anthocyanin protocols place a 105–210 mg dose one to two hours before the session rather than dividing it.

  • Half-life: The intact molecule peaks within one to two hours and clears quickly, but labeled metabolites persist 12 to 50 hours, which is why once-daily dosing still maintains metabolite exposure.

  • Split versus single dosing: Trials showing metabolic effects used twice-daily dosing; trials showing artery-dilation effects used both. Splitting is the conservative default because it smooths the short-lived peak of the parent compound.

  • Genetic considerations: Fast catechol-O-methyltransferase and sulfotransferase 1A1 variants shorten metabolite exposure and would argue for split dosing, but no trial has stratified dose by genotype, so this remains inference.

  • Sex-based differences: No trial has published sex-specific dosing. The observational mortality signal was stronger in men, and women with low iron stores have a timing rather than a dosing consideration.

  • Age-related considerations: Cognition trials in adults aged 60 to 80 used the same 320 mg daily dose as trials in middle-aged adults, with no reported tolerability difference. No dose reduction for age is established.

  • Baseline biomarkers: Response scales with distance from optimal. Elevated inflammation markers, fasting glucose above 100 mg/dL, or impaired artery dilation identify those most likely to register measurable change.

  • Pre-existing conditions: Type 2 diabetes, prediabetes and fatty liver disease are the states where the standard dose produced measurable change. Healthy adults register vascular rather than metabolic effects.

Discontinuation & Cycling

  • Lifelong or short-term: Framed as a dietary constituent rather than a course of treatment, so continuous intake is the default. Trials ran 4 to 24 weeks; nothing longer has been formally studied.

  • Withdrawal effects: None documented. No trial reported rebound in any measured marker after the intervention stopped, and no withdrawal syndrome has been described for any anthocyanin.

  • Tapering protocol: Not applicable. Metabolites clear within roughly two days of the last dose, and abrupt discontinuation carries no described consequence, so tapering serves no purpose.

  • Cycling: No tolerance has been documented, so cycling has no evidence base. Some users pause around hard training blocks or before surgery, which is a risk decision rather than an efficacy one.

Sourcing and Quality

  • Preferred forms: Purified bilberry-plus-blackcurrant anthocyanin capsules, the material used in most trials, and black rice extracts standardized to cyanidin-3-glucoside. Whole-berry powders deliver far less pigment per capsule.

  • What to look for: A label stating milligrams of cyanidin-3-glucoside, not just “total anthocyanins” or “total polyphenols”, plus a batch certificate of analysis using liquid chromatography-mass spectrometry rather than a colorimetric estimate.

  • Third-party testing: Independent verification through NSF International, USP or Informed Choice matters more than usual here, because chemical fingerprinting studies show bilberry ingredients are routinely substituted with cheaper berries or dye-boosted material.

  • Named suppliers used in research: The Norwegian preparation Medox supplied the purified anthocyanin capsules for the metabolic and cognition trials; CurraNZ supplied the New Zealand blackcurrant extract used in the exercise studies. Both were manufacturer-supplied.

  • Stability and storage: Anthocyanins degrade with heat, light and neutral acidity. Sealed, cool, dark storage preserves content; gummy and liquid formats are poor carriers, and products past their date likely underdeliver.

Practical Considerations

  • Time to effect: Artery dilation improves within one to two hours of a single dose. Inflammatory and metabolic markers need 6 to 12 weeks, and glucose tolerance changes were measured at 12 weeks.

  • Common pitfall — buying by total anthocyanins: Products stating only total anthocyanin content may be delphinidin- or malvidin-dominant, and the structure-stratified pooling shows those behave differently from cyanidin on metabolic endpoints.

  • Common pitfall — expecting lipid effects: The widely repeated cholesterol claim comes from mixed-anthocyanin trials and did not reproduce when cyanidin was isolated, so a lipid panel is a poor way to judge whether it is working.

  • Regulatory status: Sold as a dietary supplement in the United States with no pre-market approval, and permitted as food color E163 in the European Union. It is not an approved drug in any jurisdiction.

  • Cost and accessibility: Widely available online at roughly USD 20–60 per month at trial doses, so cost is not a barrier. No prescription, compounding pharmacy or clinical supervision is required to obtain it.

  • Funding and payer landscape: No insurer or health system reimburses it and none has a stake in it displacing a drug, so payer bias is absent. Berry grower boards and extract manufacturers fund much of the trial literature on all sides.

Interaction with Foundational Habits

  • Sleep: No direct interaction. Neither purified anthocyanins nor cyanidin-3-glucoside has shown a sleep effect in controlled trials, and there is no stimulant or sedative mechanism. Tart cherry products marketed for sleep act through their melatonin content, not their pigment, so timing relative to bedtime is unconstrained.

  • Nutrition: Direct and bidirectional. Absorption uses intestinal sugar transporters, so dosing with a carbohydrate-containing meal is the tested condition. Gut bacteria generate the active breakdown products, making fiber intake a determinant of response. Dairy protein binds polyphenols and may reduce uptake, so protocols separate dosing from milk-based drinks.

  • Exercise: Potentiating for performance, possibly blunting for adaptation. Blackcurrant anthocyanins taken one to two hours before endurance work produced a small pooled performance gain. The countervailing concern is that antioxidant loading suppresses the free-radical signals driving mitochondrial adaptation, which has never been tested for anthocyanins specifically.

  • Stress management: Indirect. The measured effect is on inflammatory messengers rather than on the stress-hormone axis; no trial has measured cortisol after anthocyanin supplementation. Chronic psychological stress raises the inflammatory markers this compound modestly lowers, so the two work on the same endpoint by different routes.

Monitoring Protocol & Defining Success

Because response scales with how far a marker sits from optimal, a baseline panel drawn before the first dose is what makes any later change interpretable. A fasting metabolic and inflammatory panel, blood pressure and a subjective symptom baseline are recorded in the week before starting. For anyone on insulin, a sulfonylurea or warfarin, a pre-start glucose or clotting-time reading is added for comparison.

The panel is repeated at 12 weeks, the shortest interval at which metabolic and inflammatory changes appeared in trials, then every 6 to 12 months on continued use. Protocols add daily capillary glucose for the first 4 weeks in people taking glucose-lowering drugs, and clotting-time rechecks at 1 and 2 weeks in people on warfarin. Success is movement of at least one baseline-abnormal marker toward its optimal range, not a normal result on a panel that was already normal.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
High-sensitivity C-reactive protein Below 0.5 mg/L Primary inflammation target and the strongest predictor of who responds Conventional labs call anything under 3.0 mg/L normal; defer testing 2 weeks after any infection
Fasting glucose 75–86 mg/dL Tracks the best-supported metabolic effect Conventional range runs to 99 mg/dL; requires a 10–12 hour fast
Hemoglobin A1c 4.8–5.3% Three-month average blood sugar, the endpoint moved in animal work Hemoglobin A1c is glycated hemoglobin; conventional cutoff is 5.7%. Falsely low with anemia
Fasting insulin 2–5 µIU/mL Detects insulin-sensitivity change earlier than glucose Conventional labs call anything up to 25 µIU/mL normal; pair with fasting glucose to calculate HOMA-IR (homeostasis model assessment of insulin resistance), target below 1.0
Apolipoprotein B Below 80 mg/dL Tests the contested lipid claim honestly, counting particles rather than cholesterol mass Conventional cut-points sit at 90–130 mg/dL; apolipoprotein B is the protein on every artery-damaging particle; non-fasting sampling is acceptable
Alanine aminotransferase 10–26 U/L (men), 10–19 U/L (women) Liver signal that moved in the fatty liver pilot Conventional upper limits near 40 U/L are far above the functional target; avoid intense exercise for 48 hours before
Ferritin 30–100 ng/mL Guards against the iron-binding interaction Conventional ranges extend to roughly 300 ng/mL; an acute-phase reactant, so pair with high-sensitivity C-reactive protein to interpret a high value
Blood pressure Below 120/80 mmHg Cheapest read on vascular effect, though pooled trials show no change Seated, after 5 minutes rest, averaged over 3 readings on 2 days
Flow-mediated dilation No established target; track change from the individual’s own baseline Directly measures the best-supported benefit Specialist ultrasound, rarely available outside research; a rise of about 1.5 percentage points is the pooled expectation

Qualitative markers worth tracking alongside the panel:

  • Daytime energy and afternoon slump severity
  • Visual comfort and eye strain after long screen sessions
  • Soreness and readiness in the 24–48 hours after hard training
  • Subjective cognitive clarity and word-finding ease
  • Digestive comfort, especially in the first two weeks

Emerging Research

  • Metabolite-first neuroscience: NCT06594848, a University of California, Davis study in 12 healthy adults, tests whether black rice extract and its anthocyanidin breakdown products raise brain-derived neurotrophic factor, a protein supporting neuron growth and survival.

  • Cardiac surgery prophylaxis: NCT05991700, a University of Michigan phase 1/2 trial in 70 patients, tests anthocyanin-rich table grape powder for preventing post-operative atrial fibrillation, an irregular heart rhythm common after cardiac surgery.

  • Largest berry intervention trial: NCT03620266 enrolls 900 participants after myocardial infarction or type 2 diabetes to test bilberry and oat intake, with plasma LDL cholesterol as its registered primary endpoint.

  • Cerebral perfusion in aging: NCT07177781, a Maastricht University trial in 36 older adults, measures brain insulin sensitivity, brain vascular function and cerebral blood flow after wild blueberry consumption.

  • Blood pressure at scale: NCT07734948 enrolls 300 pre-hypertensive adults in Peru to test purple-fleshed potatoes, addressing the one cardiometabolic endpoint that pooled anthocyanin trials have consistently failed to move.

  • Structure-specific trials could weaken the case: The cyanidin-versus-delphinidin pooling (Araki et al., 2021) and the null isolated-compound crossover (Aboufarrag et al., 2022) both suggest that isolating cyanidin-3-glucoside may remove effects seen with mixtures. Replication would narrow its case sharply.

  • Metabolite pharmacology could strengthen it: The isotope-tracer work (Czank et al., 2013) from trial NCT01106729 implies that breakdown products, not the pigment, are the agents. Dosing those directly would test the mechanism properly.

  • Personalization by inflammatory phenotype: A reanalysis of the dementia-risk trial (Borda et al., 2024) found cognitive benefit confined to a high-inflammation cluster. A prospective trial enrolling only that phenotype would settle whether the cognition signal is real.

Conclusion

Cyanidin-3-glucoside is the most common of the colored plant pigments called anthocyanins. Very little of it reaches the bloodstream unchanged; most of what circulates is smaller breakdown compounds. That single fact shapes how its effects should be read.

The clearest human signal is on blood vessel flexibility: when many trials are combined, arteries widen better after supplementation, and this is the one finding that survives when the cyanidin family is separated from its chemical relatives. A second, narrower signal appears in people whose blood sugar handling is already impaired, where capsules of purified berry pigments have restored more normal responses. Claims for blood fats, body weight, liver measures, memory and athletic recovery fade once all the trials are counted together, and when the isolated molecule was tested against a dummy capsule, nothing moved.

Safety looks unremarkable. Trials lasting up to half a year recorded no serious problems. The practical concerns are stomach upset, added blood-sugar lowering alongside diabetes medicines, and products that do not contain what the label states.

Two weaknesses in the evidence base deserve naming. Most influential supplement trials used a single commercial berry-pigment preparation, frequently supplied by its manufacturer, and berry grower boards fund much of the exercise and cognition work; almost none of it tested the isolated molecule. Whether the effects belong to this pigment, to its close relatives, or to its breakdown products is unsettled.

Top - Benefits - Risks - Protocol